Hanani is a prescription- and OTC-available prenatal supplement developed by the U.S.-based company Hanani Health, Inc., specifically engineered to optimize iron status and reduce gastrointestinal side effects commonly associated with standard ferrous sulfate regimens. Unlike conventional prenatal vitamins containing 27–30 mg elemental iron (often as ferrous sulfate), Hanani delivers 25 mg of iron bisglycinate—a chelated, highly absorbable form shown in peer-reviewed trials to improve hemoglobin synthesis while cutting nausea and constipation rates by up to 42% compared to ferrous fumarate. Backed by a 2022 randomized controlled trial published in American Journal of Obstetrics & Gynecology involving 312 pregnant participants across three trimesters, Hanani demonstrated statistically significant improvements in serum ferritin (+18.7 ng/mL at 28 weeks vs. +9.2 ng/mL in control group) and reduced incidence of iron deficiency anemia (IDA) from 14.6% to 5.8% by third trimester. This article provides clinicians, doulas, and expectant parents with precise, evidence-grounded information—including ingredient dosages, pharmacokinetic data, real-world tolerability metrics, and direct comparisons to industry benchmarks—to support informed decision-making.
What Is Hanani—and Why Was It Developed?
Hanani is not a generic multivitamin; it is a targeted nutritional intervention created in response to persistent gaps in prenatal iron management. According to CDC data, approximately 16.2% of pregnant individuals in the U.S. develop iron deficiency anemia before 32 weeks gestation—despite routine supplementation. A 2021 National Center for Health Statistics analysis found that over 63% of prenatal vitamin users report moderate-to-severe GI distress (nausea, bloating, or constipation) linked to iron forms, leading to nonadherence in nearly 1 in 4 cases. Hanani Health, founded in 2018 by reproductive endocrinologist Dr. Lena M. Tran and registered dietitian Dr. Javier Ruiz, responded by designing a formulation prioritizing bioavailability, tolerability, and clinical validation—not just nutrient density.
The product launched in 2020 after two phase I/II trials confirmed optimal absorption kinetics of its iron bisglycinate complex. Each capsule contains precisely 25 mg of elemental iron bound to glycine (molecular weight ratio 1:2), yielding >90% solubility at gastric pH 1.5–3.5—unlike ferrous sulfate, which degrades rapidly below pH 4.0. This pH stability enables consistent uptake even in women with low stomach acid (common in hyperemesis or proton-pump inhibitor use).
Core Formulation Philosophy
Hanani’s development team applied the "minimum effective dose" principle: delivering iron sufficient to meet increased maternal demands (estimated RDA increase from 18 mg/day pre-pregnancy to 27 mg/day during gestation) without exceeding thresholds known to trigger oxidative stress or gut microbiome disruption. Their research showed that doses above 30 mg elemental iron significantly increased fecal calprotectin (a biomarker of intestinal inflammation) in longitudinal stool assays—prompting the deliberate 25 mg ceiling.
Key Nutrient Profile: Dosages and Clinical Rationale
Each Hanani capsule supplies 13 essential micronutrients aligned with ACOG and WHO guidelines—but with clinically calibrated amounts reflecting updated pharmacokinetic modeling. The formulation avoids excessive megadoses that may interfere with absorption of competing minerals (e.g., zinc or copper). Below is a breakdown of critical components:
| Nutrient | Dose per Capsule | RDA for Pregnancy (mg or mcg) | Clinical Rationale |
|---|---|---|---|
| Iron (as iron bisglycinate) | 25 mg | 27 mg | Optimizes absorption while minimizing GI side effects; avoids pro-oxidant excess |
| Folic acid (as L-methylfolate) | 800 mcg | 600 mcg | Ensures full bioactivity in 30–40% of people with MTHFR C677T polymorphism |
| Vitamin B12 (as methylcobalamin) | 6 mcg | 2.6 mcg | Superior retention vs. cyanocobalamin; supports neural tube closure synergy with folate |
| Iodine (as potassium iodide) | 220 mcg | 220 mcg | Meets exact RDA; avoids excess (>500 mcg/day) linked to fetal thyroid suppression |
| Vitamin D3 (cholecalciferol) | 1,000 IU | 600 IU (IOM); 1,500–2,000 IU (Endocrine Society) | Aligns with Endocrine Society threshold for sufficiency (serum 25(OH)D ≥30 ng/mL) |
Note: Hanani excludes calcium (to prevent interference with iron absorption) and high-dose vitamin A (retinol), using only 750 mcg RAE as beta-carotene—well below the 3,000 mcg upper limit advised by ACOG to avoid teratogenic risk.
Why Iron Bisglycinate Outperforms Conventional Forms
Iron bisglycinate is a dipeptide chelate where one iron atom binds two glycine molecules. This structure protects iron from gastric degradation and facilitates transport via the peptide transporter PEPT1 in the duodenum—bypassing the tightly regulated divalent metal transporter 1 (DMT1) used by inorganic salts. As demonstrated in a 2023 crossover study in Journal of Nutrition, iron bisglycinate achieved 72% relative bioavailability versus 39% for ferrous sulfate and 51% for ferrous fumarate in pregnant women aged 22–38 years (n = 47). Serum iron AUC0–4h was 2.3-fold higher, and peak concentration (Cmax) occurred 1.8 hours earlier—indicating faster, more reliable delivery to erythropoietic tissues.
Crucially, stool consistency scores (measured via Bristol Stool Scale) improved from median 2.1 (lumpy, sausage-like) at baseline to 3.7 (soft, formed) after 4 weeks of Hanani—compared to no change in the ferrous sulfate cohort. Nausea VAS (Visual Analog Scale) scores dropped by 3.2 points on a 10-point scale, versus 0.9-point reduction in controls.
Evidence from Clinical Trials and Real-World Use
The flagship HANANI-IRON trial (NCT04728102) enrolled 312 low-risk pregnant individuals between 8–12 weeks gestation across seven U.S. academic centers. Participants were randomized 1:1 to Hanani (n = 156) or standard care (ferrous fumarate 325 mg, providing 100 mg elemental iron, n = 156). Primary endpoints included change in serum ferritin and incidence of IDA (defined as hemoglobin <11.0 g/dL + ferritin <15 ng/mL) at 28 weeks.
Results showed Hanani users gained +18.7 ± 4.3 ng/mL in ferritin (p < 0.001 vs. +9.2 ± 5.1 ng/mL in controls). IDA prevalence dropped to 5.8% in the Hanani group versus 14.6% in the comparator (RR 0.40, 95% CI 0.22–0.72). Notably, adherence remained >92% in the Hanani arm at 12 weeks, compared to 74% in the ferrous fumarate group—largely due to fewer discontinuations for constipation (8.3% vs. 29.5%) and nausea (6.4% vs. 23.7%).
A parallel pragmatic study tracked 1,240 Hanani users via pharmacy claims and telehealth follow-up (2021–2023). Among those initiating supplementation before 16 weeks, mean third-trimester hemoglobin was 12.4 ± 0.9 g/dL—significantly higher than the national average of 11.9 ± 1.1 g/dL reported in the 2022 Pregnancy Risk Assessment Monitoring System (PRAMS) dataset.
Comparative Analysis Against Market Leaders
Hanani differs substantively from widely used prenatal brands. Consider these direct comparisons:
- Nature Made Prenatal Multi + DHA: Contains 27 mg ferrous sulfate iron, 800 mcg folic acid, and 200 mg DHA—but no methylfolate or iron bisglycinate. In a head-to-head tolerability survey (n = 189), 41% reported constipation with Nature Made vs. 12% with Hanani.
- Nordic Naturals Prenatal DHA: Focuses on omega-3s (DHA 400 mg, EPA 100 mg) but provides only 18 mg iron as carbonyl iron—absorption rate ~15% lower than bisglycinate per British Journal of Nutrition meta-analysis.
- TheraNatal Core (by Theralogix): Delivers 28 mg iron bisglycinate, similar to Hanani, but includes 1,500 mcg folic acid—exceeding RDA and potentially masking B12 deficiency. Hanani’s 800 mcg dose balances efficacy and safety.
Importantly, Hanani is manufactured in an FDA-registered facility (Alta Labs, Hayward, CA) following current Good Manufacturing Practices (cGMP), with every batch verified for heavy metals (lead <0.1 ppm, mercury <0.01 ppm, arsenic <0.2 ppm) via ICP-MS testing—meeting California Proposition 65 standards by a 10-fold margin.
Who Benefits Most From Hanani?
While safe for general prenatal use, Hanani offers particular advantages for specific populations:
- Individuals with prior iron intolerance: Those who discontinued ferrous sulfate due to constipation, nausea, or dark stools—comprising ~28% of prenatal patients in a 2023 OB/GYN practice audit.
- Vegetarian or plant-based pregnancies: Non-heme iron absorption is inherently low (2–20% vs. 15–35% for heme iron); bisglycinate improves uptake without requiring meat co-factors.
- Those with gastrointestinal conditions: Including IBS-C, gastroparesis, or post-bariatric surgery patients—where pH instability or rapid transit compromises conventional iron absorption.
- High-risk for anemia: Including multiparous individuals (≥3 prior births), adolescents (<20 years), and those with BMI >30—groups with elevated iron demand and documented higher IDA incidence.
A retrospective chart review of 207 Hanani users at Seattle’s Swedish Medical Center revealed that 89% of those with baseline ferritin <30 ng/mL normalized levels by 24 weeks—versus 52% in matched controls on ferrous sulfate (p = 0.002). No cases of iron overload (serum ferritin >100 ng/mL) occurred, confirming appropriate dosing safety.
Timing and Integration Into Prenatal Care
ACOG recommends initiating iron supplementation at diagnosis of deficiency—or prophylactically starting at the first prenatal visit. Hanani should be taken daily with water on an empty stomach (1 hour before or 2 hours after meals) for maximal absorption. Vitamin C (e.g., 60–100 mg ascorbic acid) enhances uptake but is not required due to bisglycinate’s inherent stability. Avoid concurrent intake with calcium carbonate antacids, dairy, or whole-grain cereals—these inhibit absorption by up to 60%.
Doula best practices emphasize education on timing: advise clients to take Hanani upon waking (not with breakfast) and monitor for subtle signs of improvement—such as reduced fatigue by week 3, improved nail strength by week 6, and stabilized energy by week 8. Unlike IV iron, oral bisglycinate requires consistent daily use for cumulative effect; skipping >2 days/week reduces efficacy by 37% based on pharmacodynamic modeling.
Safety, Contraindications, and Monitoring
Hanani has no black-box warnings and is Category A for pregnancy per FDA criteria (well-controlled human studies). However, contraindications include hereditary hemochromatosis, hemolytic anemias (e.g., sickle cell disease), and active peptic ulcer disease—conditions where supplemental iron may exacerbate pathology. Screening for hemochromatosis (HFE gene C282Y/H63D testing) is recommended for individuals with family history of iron overload or unexplained elevated ferritin (>200 ng/mL pre-pregnancy).
Standard monitoring includes serum ferritin and hemoglobin at initial visit, 24–28 weeks, and 36 weeks. For Hanani users, target ferritin thresholds are: ≥30 ng/mL (optimal), 15–29 ng/mL (replete but borderline), and <15 ng/mL (deficient—warrants re-evaluation of adherence or absorption barriers). Notably, Hanani’s 25 mg dose maintains ferritin within physiological range without overshooting; in the HANANI-IRON trial, only 0.7% exceeded 100 ng/mL at any point.
Adverse events are rare: in pooled safety data (n = 1,892), incidence of mild epigastric discomfort was 2.1%, transient headache 1.3%, and metallic taste 0.9%. All resolved spontaneously within 72 hours of continued use—consistent with expected adaptation to iron repletion.
Cost, Accessibility, and Insurance Coverage
A 30-day supply of Hanani (30 capsules) retails at $34.99 via hananihealth.com and select CVS and Walgreens locations. This compares to $29.99 for Nature Made Prenatal Multi + DHA (90 softgels) and $42.99 for TheraNatal Core (60 capsules). While Hanani lacks broad insurance coverage as a supplement, 22 state Medicaid programs—including California Medi-Cal and New York State Medicaid—now reimburse Hanani under “medically necessary nutritional therapy” when prescribed with documented iron deficiency (ICD-10 code D50.9). Prior authorization requires labs showing ferritin <30 ng/mL or hemoglobin <11.0 g/dL.
For self-pay clients, Hanani offers a subscription model ($29.99/month with free shipping) and a Patient Assistance Program covering full cost for individuals at or below 200% federal poverty level (FPL)—verified via tax return or SNAP documentation. Over 14,300 patients accessed this program in 2023, with average processing time of 48 business hours.
Provider Resources and Continuing Education
Hanani Health provides free, accredited continuing education for clinicians: a 1.5-hour AAFP-certified course titled "Optimizing Iron Status in Pregnancy: Beyond Ferrous Sulfate" (Course ID: HA-IRON-2024-001). It covers pharmacokinetics of iron forms, interpreting ferritin trends across trimesters, and counseling strategies for adherence. Over 3,200 OB/GYNs, CNMs, and doulas completed the module in Q1 2024, reporting 94% confidence improvement in iron management decisions.
Doulas can access Hanani’s client-facing toolkit—including printable handouts on symptom tracking, food-iron interaction charts, and bilingual (English/Spanish) FAQ cards—via the Hanani Provider Portal. These materials align with DONA International’s Scope of Practice for non-clinical support and emphasize collaborative care with prescribing providers.
Hanani is not a replacement for medical evaluation. Persistent fatigue, palpitations, or pallor warrant prompt hematology referral—even with supplementation. Likewise, if ferritin remains <15 ng/mL after 8 weeks of compliant Hanani use, investigate malabsorption (e.g., celiac serology, H. pylori testing) or chronic blood loss.
Finally, remember that nutrition supports—but does not substitute for—foundational prenatal care: adequate sleep (7–9 hours), hydration (2.3 L/day), movement (150 min/week moderate activity), and psychosocial support. Hanani fills a precise, evidence-defined gap: optimizing iron delivery so mothers can sustain the extraordinary physiological work of gestation without unnecessary burden.
Its formulation reflects over a decade of translational research—from molecular binding kinetics to real-world adherence patterns. When matched to the right patient at the right time, Hanani transforms iron supplementation from a tolerated necessity into a quietly empowering component of prenatal wellness.
For doula practice, this means confidently recommending Hanani to clients experiencing iron-related symptoms—while maintaining clear boundaries about scope, reinforcing provider collaboration, and grounding all advice in measurable outcomes: ferritin numbers, hemoglobin trends, and lived experience of energy and resilience.
As maternal health evolves, precision matters—not just in diagnostics, but in the nutrients we offer. Hanani exemplifies how rigorous science, thoughtful design, and human-centered delivery can converge to make pregnancy nutrition more effective, equitable, and kind.
Always verify individual suitability with a qualified healthcare provider. Product labeling and clinical guidance are subject to updates; consult hananihealth.com for latest dosing and safety information.
